Xavier Duportet

USPTO Granted Patents = 23 (Patent Applications = 16)

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 3.1

ph-index = 2

Forward Citations = 22(Granted Patents)

Company Filing History:

Massachusetts Institute of Technology

patents

4. 1 out of 2

Inria (french Institute for Research in Computer Science and Automation)

patents

5. 1 out of 3

Kantonsspital St. Gallen

patents

where one patent can have more than one assignee

Years Active: 2020-2025

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12214070 - Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins (2025-02-04),

2. 12214022 - Sequence-specific antimicrobials by blocking DNA repair (2025-02-04),

3. 12098372 - Microbiome modulation of a host by delivery of DNA payloads with minimized spread (2024-09-24),

4. 11970716 - Transcriptional control in prokaryotic cells using DNA-binding repressors (2024-04-30),

5. 11952594 - Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof (2024-04-09),

6. 11946056 - Optimized vector for delivery in microbial populations (2024-04-02),

7. 11905516 - Optimized vector for delivery in microbial populations (2024-02-20),

8. 11839645 - Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins (2023-12-12),

9. 11746352 - Microbiome modulation of a host by delivery of DNA payloads with minimized spread (2023-09-05),

10. 11690880 - Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders (2023-07-04),

11. 11633348 - Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins (2023-04-25),

12. 11617773 - Elimination of colonic bacterial driving lethal inflammatory cardiomyopathy (2023-04-04),

13. 11584918 - Transcriptional control in prokaryotic cells using DNA-binding repressors (2023-02-21),

14. 11584781 - Chimeric receptor binding proteins resistant to proteolytic degradation (2023-02-21),

15. 11541106 - Method for killing bacteria with an engineered postbiotic (2023-01-03),

Title: Xavier Duportet - Innovator from Paris, FR

Introduction: Xavier Duportet is a renowned inventor based in Paris, France, known for his groundbreaking contributions to the field of biotechnology and synthetic biology.

Latest Patents: Xavier Duportet holds several patents in the areas of genetic engineering, molecular biology, and biotechnology, showcasing his innovative approach to solving complex biological challenges.

Career Highlights: With a background in both biology and computer science, Xavier Duportet founded Eligo Bioscience, a biotechnology company focused on developing precision medicines using synthetic biology techniques. His work has been instrumental in advancing the field and has garnered international recognition.

Collaborations: Xavier Duportet has collaborated with leading research institutions, universities, and biotech companies worldwide to further the application of synthetic biology in healthcare, agriculture, and environmental sustainability. His collaborative efforts have led to significant advancements in the field.

Conclusion: Xavier Duportet's passion for innovation and his interdisciplinary approach have positioned him as a key figure in the field of biotechnology, with a lasting impact on the future of healthcare and sustainability.

This text is generated by artificial intelligence and may not be accurate.